WO2012102875A2

WO2012102875A2 - Analgesic compounds, methods, and formulations

Info

Publication number: WO2012102875A2
Application number: PCT/US2012/021181
Authority: WO
Inventors: Jean Marie Defauw; Scott Dale HOLMSTROM; Shuhui Chen; Yang Zhang; Wentao Wu; Xian PENG; Yujuan MA; Lun LU
Original assignee: Eli Lilly and Co
Current assignee: Eli Lilly and Co
Priority date: 2011-01-27
Filing date: 2012-01-13
Publication date: 2012-08-02
Anticipated expiration: 2013-07-27
Also published as: CN105753723B; WO2012100423A1; ZA201304786B; SG192131A1; AR126189A2; CN105753723A; US8802728B2; MX345518B; CA2825816C; KR101612168B1; IN2013MN01164A; US20130225679A1; TWI564275B; MX2013008708A; NZ612731A; AU2012209430A1; BR112013018527B1; WO2012102875A3; EP2668152B1; IL227250A

Abstract

Provided are analgesic compounds, and salts thereof, of formula: ( I ) wherein A is: ( A ) Additionally, pharmaceutical formulations and methods of use employing the above compounds are provided.

Description

AN ALGESIC COMPOUNDS, METHODS, AND FORMULATIONS

Opiates, a class of centrally acting compounds, are the most frequently used agents for pain control and alleviation, and which act upon one or more of the human or mammal opiate receptors. Technically, opiates are the natural alkaloids found in the resin of the opium poppy, but current usage of the term includes synthetic variations, termed opioids. Opiates are narcotic agonistic analgesics and are drugs including or derived from opium, such as morphine, codeine, and many synthetic congeners of morphine, with morphine and hydrocodone preparations being the most widely used opiates. Opiates are natural and synthetic drugs with morphine-like actions, and are subject to control under U.S. Federal narcotics law (scheduled drugs) and the laws of most other nations and international organizations because of their addicting properties and the subsequent destructive toll exacted on the abusers and those with any connection to them.

Tramadol is a synthetic analog of the phenanthrene alkaloid codeine and, as such, is an opioid and also a prodrug (codeine is metabolized to morphine, tramadol is converted to M-l also called O-desmethyltramadol). Tramadol, like the opiates, is associated with adverse effects, such as physical and psychological dependence, severe withdrawal symptoms, as well as other somewhat less serious side-effects, including nausea, vomiting, sweating, constipation, and drowsiness.

While the opiates and related drugs clearly serve useful purposes, alternative therapies and compounds for alleviation of pain are desirable due to the known problems of the opiates. Particularly, compounds which are not scheduled, allow for lower dosing frequency, and/or do not exhibit the side-effects either at all or to the degree associated with the opiates and related drugs, would provide such alternative therapies.

Provided are analgesic compounds, and salts thereof, of formula I:

I wherein A is

R¹ is hydrogen, C₁-C₅ alkyl, C₁-C₅ alkoxy, C₁-C₅ haloalkyl, C₁-C₅ alkanol, -(C₁-C₅ alkyl)phenyl, or phenyl, or a group of the formula -C(0)-R¹², where R¹² may be C₁-C₅ alkyl, C₁-C₅ alkoxy, C₁-C₅ haloalkyl, C₁-C₅ alkanol, -(C₁-C₅ alkyl)phenyl, or phenyl;

R² is hydrogen, C₁-C5 alkyl, C₁-C5 alkoxy, halogen, C₁-C5 haloalkyl, or C₁-C5 haloalkoxy;

R³ is hydrogen, C₁-C₅ alkyl, C₁-C₅ alkoxy, halogen, C₁-C₅ haloalkyl, or C₁-C₅ haloalkoxy;

R⁴ is hydrogen, C₁-C5 alkyl, or -(C₁-C5 alkyl)phenyl;

R⁵ is hydrogen, C₁-C₅ alkyl, or -(C₁-C₅ alkyl)phenyl;

R⁶ is hydrogen, hydroxy, or is absent;

R⁷ is hydrogen;

R⁸ is hydrogen or methyl;

R⁹ is hydrogen or methyl;

R¹⁰ is hydrogen;

R¹¹ is hydrogen or C₁-C₅ alkyl;

or R⁷ and R¹⁰ combine to form -CH₂- or -(CH₂)₂-;

or R⁸ and R⁹ combine to form a cyclopropyl group with the carbon to which they are attached;

or R¹⁰ and R¹¹ combine to form -CH₂- or -(CH₂)₃- .

More particularly, A may be:

Of the first four definitions immediately above for A, the following are preferred:

C₁-C5 alkyl refers to straight chain and branched alkyls having one to five carbon atoms, and includes methyl, ethyl, propyl, n-butyl, iso-butyl, pentyl, isopentyl, and neopentyl.

C₁-C5 alkoxy refers to straight chain and branched alkoxys having one to five carbon atoms, and includes methoxy, ethoxy, propoxy, n-butoxy, iso-butoxy, pentoxy, isopentoxy, and neopentoxy.

Halogen or halo refers to fluorine, bromine, chlorine, and iodine.

Haloalkyl as used herein refers to an alkyl (as noted above) substituted with one or more halo atoms. Such groups include trifluoromethyl, methylchloride, dichloromethyl, pentylchloride, butyl chloride, and isopropyl chloride.

Haloalkoxy refers to an alkoxy group, as described herein, which is substituted with one to six halo groups. Examples of fluoroalkoxy groups include fluoromethoxy,

difluoromethoxy, trifluoromethoxy, pentafluoroethoxy, and trifluoroethoxy.

C₁-C5 alkanols refer to methanol, ethanol, propanol, or methoxyethanol.

In the definition of A:

PivCl refers to pivaloyl chloride.

Controlling pain refers to either suppressing, inhibiting, ameliorating, reducing, or eliminating pain, its severity, and/or duration. As such, the invention is applicable to the alleviation of existing pain as well as the suppression or inhibition of pain which would otherwise ensue from an imminent pain-causing event. The pain being alleviated can be chronic or acute.

Mammal includes both human or non-human mammals. Non-human mammals include domestic animals, such as livestock animals and companion animals. Livestock animals include cattle, camellids, pigs, sheep, goats, and horses. Companion animals include dogs, rabbits, cats, and other pets owned and maintained in close association with humans as part of the human-animal bond.

Effective amount refers to the amount of a compound of formula I, or a salt thereof, sufficient to control or alleviate pain in a mammal in need thereof, and as such will depend upon several factors. Ranges for a compound of formula I, or a salt thereof, in the methods include from 0.01 to 1000 mg/kg and more desirably, 0.1 to 100 mg/kg of the animal's body weight. The frequency of the administration will also be dependent upon several factors, and can be a single dose administered once a day or once a week for a duration determined by the attending doctor or veterinarian. The dose can be also be split into two or more smaller doses given in a timeframe to result in the control or alleviation of pain.

Pharmaceutically acceptable as used in this application, for example with reference to salts and formulation components such as carriers, includes "veterinarily acceptable", and thus includes both human and animal applications independently.

Pharmaceutically acceptable salts, and common methodology for preparing them, are known in the art. See, e.g., P. Stahl, et al, HANDBOOK OF PHARMACEUTICAL SALTS:

PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002); S.M. Berge, et al,

"Pharmaceutical Salts," Journal of ^'Pharmaceutical Sciences, Vol. 66, No. 1, January 1977. A preferred salt is the hydrochloride salt.

The compounds of formula I and their salts may be formulated as pharmaceutical compositions for systemic administration. Such pharmaceutical compositions and processes for making the same are known in the art for both humans and non-human mammals. See, e.g.,

REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, (A. Gennaro, et al, eds., 19^th ed., Mack Publishing Co., 1995). Additional active ingredients may be included in the formulation containing a compound of formula I or a salt thereof.

Carrier is used herein to describe any ingredient other than the active component(s) in a formulation. The choice of carrier will to a large extent depend on factors such as the particular mode of administration, the effect of the carrier on solubility and stability, and the nature of the dosage form.

The compounds of the invention may be made by the following described procedures, as well as the procedures described in Selnick, H. C; Bourgeois, M. L.; Butcher, J.

W.; Radzilowski, E. M. Tetrahedron Lett, 1993, 34, 2043; Alvarado, C; Guzman, A.; Diaz, E.;

Patino. R. J. Mex. Chem. Soc. 2005, 49, 324; Evans, G. R.; Paloma, Fernandez, D.; Henshilwood, J. A., Lloyd, S.; Nicklin, C. Org. Process Res. Dev. 2002, 6, 729; and Mohacsi, E.; O'Brien, J. P.;

Blount, J. F. J.Heterocycl.Chem. 1990, 27, 1623.

The invention provides a pharmaceutical formulation comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers. The pharmaceutical formulation may further comprise at least one additional active ingredient. A pharmaceutical formulation may be a human pharmaceutical formulation or a veterinary pharmaceutical formulation. The invention provides a method of controlling pain in a mammal in need thereof comprising administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, to said mammal. The method may further provide administering at least one other active ingredient to said mammal. The mammal may be a human or non-human mammal, and further may be a companion animal, such as a dog or cat.

For compounds of the formula la, below, Schemes A-C and Preparations and/or Examples 1-76 illustrate methods of preparing them.

Preparation 1

Synthesis of 2-dimethylaminomethyl-bicyclo[3.2.1]octan-3-one

Stir a mixture of bicyclo [3.2.1 ]octan-3 -one (5.2 g, 41.9 mmol), (HCHO)_n (1.51 g, 50.3 mmol), dimethylamine hydrochloride (3.42 g, 41.9 mmol) and 0.5 mL of cone. HC1 in MeCN (50 mL) at 80 °C for 2 hours. After removal of the solvent under vacuum, dissolve the residue in H₂0 (20 mL) and wash with EtOAc (20 mL x 3). Basify the aqueous solution with NaOH to pH = 10. Extract the resultant aqueous mixture with EtOAc (60 mL x 3). The combined organic layers are washed with brine (10 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum to give crude 2-dimethylaminomethyl- bicyclo[3.2.1]octan-3-one as brown oil (5.9 g, yield: 78.7%). MS (m/z): 182 (M+l).

Example 2

Synthesis of 2-dimethylaminometh l-3-(3-methoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol.

Add dropwise a solution of t-BuLi (19.2 mL, 25.0 mmol) in hexane via syringe to a solution of l-bromo-3-methoxy-benzene (3.74 g, 20.0 mmol) in THF (60 mL) at -78 °C under N₂. After being stirred at -78 °C for 1 hour, add dropwise a solution of 2-dimethylaminomethyl- bicyclo [3.2.1 ]octan-3 -one (1.81 g, 10.0 mmol) in THF (10 mL) to the reaction mixture and stir the resultant mixture at -78 °C for additional 1 hour. Quench the reaction with saturated aqueous NH₄C1 solution (20 mL). Extract the aqueous mixture with EtOAc (50 mL x 3). The combined organic layers are washed with brine (15 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (CH₂Cl₂:MeOH = 30: 1) to afford 2-dimethy laminomethyl-3- (3-methoxy-phenyl)-bicyclo[3.2.1]octan-3-ol as white solid (1.49 g, yield: 51%). MS (m/z): 290 (M+1).

The following compounds may be prepared essentially by the method of Example 2.

lo[3.2.1]octan-3-ol

Example 14

Synthesis of 2-dimethylaminomethyl-3-(3-methoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol hydrochloride.

Add H₂0 (100 mg, 5.56 mmol) and TMSC1 (361 mg, 3.34 mmol) to a solution of 2-dimethylaminomethyl-3-(3-methoxy-phenyl)-bicyclo [3.2.1] octan-3-ol (877 mg, 3.03 mmol) in 2-butanone (60 mL). Stir the mixture at ambient temperature for 12 hours. Concentrate the mixture under vacuum to give 2-dimethylaminomethyl-3-(3-methoxy- phenyl)-bicyclo[3.2.1]octan-3-ol hydrochloride as white solid (986 mg, Yield: 100%). 1H NMR (400 MHz, D₂0) δ 7.23-7.27 (t, J= 16.4, 1H), 7.00-7.02 (d, J= 8.0, 1H), 6.95-6.96 (t, J= 4.0, 1H), 6.78-6.80 (d, J= 10.4, 1H), 3.71 (s, 3H), 3.05-3.19 (m, 1H), 2.52-2.58 (m, 4H), 2.14-2.26 (m, 4H), 2.09-2.14 (m, 2H), 2.05-2.06 (d, J= 2.4, 1H), 1.89-1.92 (m, 1H), 1.78-1.80 (m, 1H), 1.51-1.68 (m, 4H), 1.40-1.52 (m, 1H).

The following compounds may be prepared essentially by the method of Example

Scheme B

Preparation 26

Synthesis of (3-bromo-4-fluoro-phenoxy)-tert-butyl-dimethyl-silane

Add TBSCl (3.37 g, 22.37 mmol) and imidazole (1.9 g, 27.96 mmol) to a solution of 3-bromo-4-fluoro-phenol (3.56 g 18.64 mmol) in CH₂CI₂ (60 ml). Stir the solution at ambient temperature for 3 hours. Quench the reaction with water (30 mL). Extract the aqueous layer with CH₂CI₂ (30 mL x 3). The combined organic layers are washed with brine, dried over Na₂S0₄, concentrated under vacuum. The residue is purified by silica gel chromatography (petroleum ether) to give (3-bromo-4-fluoro-phenoxy)-tert-butyl- dimethyl-silane as colorless oil (5.81 g, 99%), MS (m/z): 303 (M-1). The following compounds may be prepared essentially by the method of Preparation 26.

ane TBSO^'^ ⁱⁱⁱ^ Br

Example 39

Synthesis of 2-dimethylaminomethyl-3-(2-fluoro-5-hydroxy-phenyl)-bicyclo[3.2.1 Joctan -3-ol

Cool a solution of (3-bromo-4-fluoro- phenoxy)-tert-butyl-dimethyl-silane (5.81 g, 19.03 mmol) in THF (100 mL) to -78 °C under N₂. Then add dropwise a solution of t-BuLi (14.6 mL, 19.03 mmol) in hexane via syringe to the reaction solution. After being stirred at -78 °C for 1 hour, add dropwise a solution of 2-dimethylaminomethyl-bicyclo [3.2.1]octan-3-one (2.87 g, 15.86 mmol) in THF (1.5 mL) to the reaction mixture and stir the mixture at -78 °C for additional 1 hour. Quench the reaction with 60 mL of diluted HCl (2N), and stir at ambient temperature for 2 hours. Basify the resultant mixture with K₂CO₃ to pH = 9, and extract with EtOAc (100 mL X 3). The combined organic layers are washed with brine, dried over Na₂S0₄, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (CH₂Cl₂ to CH₂Cl₂:MeOH = 10: 1) to afford 2-dimethylaminomethyl-3-(2-fluoro-5- hydroxy-phenyl)-bicyclo[3.2.1]octan-3-ol as white solid (2.38 g, yield: 51.2%). MS (m/z): 294 (M+1). The following compounds may be prepared essentially by the method of Example 39.

Ex.

Chemical name Structure Physical data

No.

40 2-Dimethylaminomethyl-3 -(

F

3 -fluoro-5 -hydroxy-phenyl)

-bicyclo[3.2.1]octan-3-ol Jl ^0H MS (m/z): 294 (M+1).

41 2-Dimethylaminomethyl-3 -(

3 -hydroxy-5 -trifluoromethy

MS (m/z): 344 (M+1).

l-phenyl)-bicyclo[3.2. l]octa

n-3-ol

Example 52

Synthesis of 2-dimethylaminomethyl-3-(2-fluoro-5-hydroxy-phenyl)-bicyclo[3.2. ljoctan -3-ol

Add H₂0 (175.1 mg, 9.73 mmol) and TMSC1 (1.057 g, 9.73 mmol) to a solution of 2-dimethylaminomethyl-3-(2-fluoro-5-hydroxy-phenyl)-bicyclo[3.2.1]octan-3-ol (2.38 g, 8.11 mmol) in 2-butanone (60 mL). Stir the reaction mixture at ambient temperature for 3 hours. After removal solvent by evaporation, wash the residue with EtOAc to give 2-dimethylaminomethyl-3- (2-fluoro-5-hydroxy-phenyl)-bicyclo[3.2.1]octan-3-ol hydrochloride as white solid (2.23 g, Yield: 83.5%). ¹H NMR (400 MHz, D₂0) δ 6.89-6.93 (m, 2H), 6.66-6.70 (m, 1H), 3.10-3.14 (m, 1H), 2.59-2.65 (m, 4H), 2.42-2.44 (d, J= 8.0,1H), 2.36-2.41 (d, J= 20.0, 3H), 2.30-2.33 (d, J= 12.0, 2H), 2.18 (s, 1H), 1.89-1.95 (m, 1H), 1.74-1.78 (m, 1H), 1.51-1.67 (m, 4H), 1.47-1.50 (m, 1H). The following compounds may be prepared essentially by the method of Example 52.

Synthesis of 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicycle

[3.2. l]oct-3-yl)-4-fluoro-phenyl ester

Stir a mixture of 2-dimethylaminomethyl-3-(2-fluoro-5-hydroxy-phenyl)-bicyclo [3.2. l]octan-3-ol (587 mg, 2.0 mmol), 2,2-dimethyl-propionyl chloride (361.5 mg, 3.0 mmol) and triethyl amine (606 mg, 6.0 mmol) in CH2CI2 (60 mL) at ambient temperature for 12 hours.

Concentrate the mixture under vacuum, and purify the residue by preparative TLC to give 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3- hydroxy-bicycle[3.2.1]oct-3-yl)-4-fluoro-phenyl ester (368 mg, Yield: 48.8%). MS (m/z): 378 (M+l). 1H NMR (400 MHz, Methanol-d4) δ 7.29-7.32 (d, J; = 6.8, J₂ = 2.8, IH), 7.14-7.19 (d, J; = 11.6, J2 = 8.8, IH), 7.01-7.05 (m, IH), 3.19-3.25 (m, IH), 2 .64-2.67 (d , J= 13.6, IH), 2.51 (s, 6H), 2.46-2.48 (m, 2H), 2.36-2.40 (m, 2H), 2.25-2.30 (m, IH) , 1.99-2.06 (m, IH), 1.78-1.85 (m, 4H), 1.61-1.65 (m, IH), 1.36 (s, 9H).

The following compounds may be prepared essentially by the method of Example 65.

Example 71

[3.2.1]oct-3-yl)-4-fluoro-phenyl ester hydrochloride

Add H₂0 (9 mg, 0.5mmol) and TMSC1 (43 mg, 0.397 mmol) to a solution of 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicycle[3.2. l]oct-3- yl)-4-fluoro- phenyl ester (150 mg, 0.397 mmol) in 2-butanone (50 mL). Stir the reaction mixture at 0 °C for 2 hours. Evaporate the mixture under vacuum to give 2,2-dimethyl- propionic acid 3-(2-dimethylaminomethyl- 3-hydroxy-bicycle [3.2.1]oct-3-yl)-4-fluoro- phenyl ester

hydrochloride as white solid (164mg, Yield: 100%). 1H NMR (400 MHz, Methanol-d4) δ

7.30-7.32 (d, J; = 6.8, J2= 2.8, IH), 7.15-7.20 (d, J_; = 11.6, J₂ = 8.8, IH) , 7.03-7.06 (m, IH), 3.28-3.31 (m, IH), 2.77-2.81 (m, 4H), 2.37-2.52 (m, 7H), 2.27 (m, lH), 2.03 (m, IH), 1.79-1.86 (m, 4H), 1.63-1.65 (m, IH), 1.38 (s, 9H).

The following compounds may be prepared essentially by the method of Example 71.

For compounds of the formula lb, below, Schemes D and E and Examples 77- 113 illustrate methods of preparing them.

Example 77

Synthesis of 3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-phenol

Add TsOH (5.0 g, 29.1 mmol) to a solution of 2-dimethylaminomethyl-3-(3- hydroxy-phenyl)-bicyclo[3.2.1]octan-3-ol (4.8 g, 17.5 mmol) in toluene (150 mL). Heat the reaction mixture to reflux for 2 hours and then quench the reaction by addition of saturated aqueous K₂CO₃ (20 mL). Extract the aqueous layer with EtOAc (60 mL x 3). The combined organic layers are washed with brine, dried over Na₂S0₄ and evaporated under vacuum. Purify the residue by preparative HPLC to yield 3-(4-dimethyl

aminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenol as white solid (2.27 g, 50.2 %). MS (m/z): 258 (M+l).

The following compounds may be prepared essentially by the method of Example

Example 91

Synthesis of 3-(4-dimethylaminomethyl-bicyclo[3.2. l]oct-2-en-3-yl)-phenol hydrochloride

Add H₂0 (392 mg, 21.8 mmol) and TMSC1 (1.4 g, 12.9 mmol) to a solution of 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenol (2.8 g, 10.9 mmol) in 2-butanone (200 mL). Stir the reaction mixture at ambient temperature for 12 hours. Collect the precipitate by filter, and wash with EtOAc (30 mL x 2), dry under vacuum to give 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenol hydrochloride as white solid (2.41 g, Yield: 75.5%). 1H NMR(400 MHz, D₂0) δ 7.20-7.24 (t, J= 15.6, IH), 6.76-6.81 (m, 2H), 6.72 (s, IH), 6.15 (d, J= 6.4, IH), 3.58-3.61 (d, J= 12.8, IH), 3.08-3.14 (t, J= 26.0, IH), 2.89-2.92 (m, IH), 2.88 (s, 3H), 2.76 (s, 3H), 2.56 (m, IH), 2.45 (m, IH), 1.72-1.83 (m, 6H).

The following compounds may be prepared essentially by the method of Example 91.

Scheme E

Example 105

Synthesis of 2,2-dimethyl-propionic acid 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-

2-en-3-yl)-phenyl ester

Stir a mixture of 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenol (200 mg, 0.778 mmol), 2,2-dimethyl-propionyl chloride (111 mg, 0.927 mmol) and triethyl amine (234 mg, 2.316 mmol) in CH₂CI₂ (40mL) at ambient temperature for 12 hours. Concentrate the mixture under vacuum, and purify the residue by Preparative TLC to give 2,2-dimethyl-propionic acid 3-(4-dimethylaminomethyl-bicyclo [3.2.1]oct-2-en-3- yl)-phenyl ester as white solid (232 mg, Yield: 87.5%). MS (m/z): 342 (M+1). 1H NMR (400 MHz, Methanol-d4) δ 7.29-7.32 (t, J = 15.6Hz, IH), 7.06-7.08 (d, J= 7.6, IH), 6.88-6.90 (d, J_; = 8.0, J₂ = 1.6, IH), 6.84-6.85 (t, J= 3.6, IH), 6.05-6.07 (d, J= 6.8, IH), 3.22-3.32 (m, IH), 2.52-2.60 (m, IH), 2.62-2.63 (m, IH), 2.37-2.41 (m, IH), 2.17 (s, 6H), 2.07-2.14 (m, IH), 1.71-1.85 (m, 6H), 1.37 (s, 9H).

The following compounds may be prepared essentially by the method of Example 105.

Ex. Chemical

Structure Physical data

o. name

2,2-Dimet

hyl-propio MS (m/z): 360 (M+l),

109 ni acid 3-(

1H NMR (Methanol-d4, 400 MHz) δ

4-dimethyl

7.10 (t, J = 9.6, 1H), 6.97 (m, 1H), aminomet

6.88 (m, 1H), 6.12 (d, J = 9.6, 1H), hyl-bicycl

3.48 (m, 1H), 2.85 (t, J = 12.4, 1H), o[3.2.1]oct

2.61 (s, 2H), 2.52 (s, 6H), 2.33 (m,

-2-en-3-yl)

1H), 1.94 (m, 1H), 1.83(m, 5H), 1.38

-4-fluoro- (s, 9H).

phenyl est

er

Isobutyric MS (m/z): 346 (M+l).

acid 3-(4

1H NMR (Methanol-d4, 400 MHz) δ

110 -dimethyla

7.10 (t, J = 9.6, 1H), 7.01 (m, 1H), minometh

6.90 (m, 1H), 6.1 1 (d, J = 6.4, 1H), yl-bicyclo[

3.50 (m, 1H), 2.85 (m, 2H), 2.62 (s,

3.2.1]oct-2

2H), 2.55 (s, 6H), 2.48 (m, 1H), 1.95

-en-3-yl)-4

(m, 1H), 1.76 (m, 5H), 1.31 (d, J =

-fluoro-ph

6.8, 6H).

enyl ester

Example 111

2-en-3-yl)-phenyl ester hydrochloride

Add H₂0 (18 mg, lmmol) and TMSC1 (75 mg, 0.69 mmol) to a solution of 2,2-dimethyl-propionic acid 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)- phenyl ester (197 mg, 0.58 mmol) in 2-butanone (70mL). Stir the reaction mixture at ambient temperature for 2 hours. Evaporate the mixture under vacuum to afford 2,2-dimethyl-propionic acid

3-(4-dimethylaminomethyl -bicyclo[3.2.1]oct-2-en-3-yl)- phenyl ester hydrochloride as white solid (219 mg, Yield: 100%). 1H NMR (400 MHz, Methanol-d4) δ 7.38-7.42 (t, J= 16.4, IH), 7.13-7.15 (d, J; = 7.2, J₂ = 0.8, IH), 6.96-6.98 (m, 2H), 6.21-6.23 (d, J= 6.8, IH), 3.68-3.71 (d, J= 12.0, IH), 3.16-3.23 (t, J= 25.6, IH), 2.99-3.00 (m, IH), 2.88-2.92 (d, J= 14.8, 6H), 2.65 (m, IH), 2.60 (m, IH), 1.95-1.98 (m, IH), 1.82-1.86 (m, 5H), 1.37 (s, 9H).

The following compounds may be prepared essentially by the method of Example 111.

For compounds of the formula Ic, below, Schemes F and G and Preparations and/or Examples 114-140 illustrate methods of preparing them.

Example 114 Synthesis of 3-(2-dimethylaminomethyl-bicyclo[3.2.1 ]oct-3-yl)-phenol

Add Pd/C (80 mg) to a solution of 3-(4-dimethylaminomethyl-bicyclo[3.2.1] oct-2-en-3-yl)-phenol (250 mg, 0.97 mmol) in MeOH (40 mL). Then stir the mixture at 25 °C for 12 hours under 45 PSI of H₂. After filtration, Concentrate the solution under vacuum to afford 3 -(2-dimethylaminomethyl-bicyclo [3.2. l]oct-3-yl)-phenol as white solid (252 mg, Yield: 100 %). MS (m/z): 260 (M+l).

The following compounds may be prepared essentially by the method of Example 114.

Ex.

Chemical name Structure Physical data No.

120 3 -(2-dimethylaminomethyl-bicyclo [3 MS (m/z):

.2.1]oct-3-yl)-5-methyl-phenol 274

(M+l).

121 [3 -(3 -methoxy-5 -methyl-phenyl)-bic MS (m/z):

yclo[3.2.1 ]oct-2-ylmethyl]-dimethyl- 288

amine

(M+l).

Example 122

Synthesis of 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct-3-yl)-phenol hydrochloride

Add H₂0 (70 mg, 3.89 mmol) and TMSC1 (126 mg, 1.17 mmol) to a solution of 3 -(2-dimethylaminomethyl-bicyclo [3.2. l]oct-3-yl)-phenol (252 mg, 0.97 mmol) in 2-butanone (30ml). Then stir the reaction mixture at ambient temperature for 12 hours. Evaporate the mixture under vacuum to give 3 -(2-dimethylaminomethyl-bicyclo [3.2.1]oct-3-yl)-phenol hydrochloride as white solid (286 mg, Yield: 99.8%).1H NMR (400 MHz, D₂0) δ 7.04-7.07 (t, J= 10.4, 1H), 6.58-6.72 (m, 3H), 2.80-2.91 (m, 1H), 2.52-2.54 (m, 3H), 2.44-2.48 (m, 3H), 2.33-2.41 (m, 1H), 2.20-2.29 (m, 1H), 2.11 (s, 1H), 1.99 (s, 2H), 1.36-1.47 (m, 8H).

The following compounds may be prepared essentially by the method of Example

Scheme G

Example 130

Synthesis of 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct

-3-yl)-phenyl ester

Stir a mixture of 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct-3-yl)-phenol (200 mg, 0.772 mmol), 2,2-dimethyl-propionyl chloride (111.6 mg, 0.927 mmol) and triethyl amine (234 mg, 2.316 mmol) in CH₂CI₂ (40 mL) at ambient temperature for 12 hours. Concentrate the mixture under reduced pressure, and purify the residue by preparative TLC to afford

2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-bicyclo[3.2.1] oct-3-yl)-phenyl ester as white solid (217 mg, Yield: 81.9%). MS (m/z): 344 (M+l). 1H NMR (400 MHz, Methanol-d4) δ 7.36-7.40 (t, J= 13.6, 1H), 7.19-7.21 (d, J= 7.2, 1H), 7.03 (s, 1H), 6.92-6.94 (d, J= 8.0, 1H), 2.97-3.03 (t, J= 23.6, 1H), 2.49-2.68 (m, 6H), 2.40-2.44 (d, J= 13.2, 1H), 2.35 (s, 2H), 2.17-2.21 (m, 2H), 1.60-1.84 (m, 8H), 1.37 (s, 9H).

The following compounds are prepared essentially by the method of Example 130.

Ex. Chemical name Structure Physical data

MS (m/z): 364 (M+l),

1H NMR (400 MHz, CDC1₃)

δ 8.19-8.22 (m, 2H),

benzoic acid 3 -(2

7.63-7.64 (t, J= 7.6, 1H),

131 -dimethylaminom

7.50-7.52 (t, J= 7.6, 2H),

ethyl-bicyclo[3.2.

0 7.32-7.36 (t, J= 16.4, 1H),

l]oct-3-yl)-pheny

7.04-7.10 (m, 3H), 2.46 (s,

1 ester

1H), 2.19-2.39 (m, 3H), 2.10

(s, 6H), 1.80-1.90 (t, J=

37.2, 1H), 1.52-1.71 (m,

9H).

Ex. Chemical name Structure Physical data

MS (m/z): 362 (M+l).

2,2-dimethyl-pro

1H NMR (Methanol-d4, 400

pionic acid 3-(2- MHz) δ 7.10 (t, J= 8.8, 2H),

134 dimethylaminom

6.90 (m, 1H), 2.92 (s, 1H),

ethyl-bicyclo[3.2.

2.43 (s, 1H), 2.33 (m, 2H),

l]oct-3-yl)-4-fluo

2.03 (s, 6H), 1.90 (s, 1H),

ro-phenyl ester

1.50-1.82 (m, 9H), 1.45 (s,

9H).

MS (m/z): 348 (M+l).

1H NMR (Methanol-d4, 400

isobutyric acid 3

MHz) δ 7.13 (t, J= 8.4, 2H),

135 -(2-dimethylamin

6.90 (m, 1H), 2.85(m, 2H),

omethyl-bicyclo

2.40 (s, 1H), 2.33 (m, 2H),

[3.2.1]oct-3-yl)-4

2.06 (s, 6H), 1.50-1.88 (m,

-fluoro-phenyl es

10H), 1.31 (d, J= 6.4, 6H).

ter

Example 136

Synthesis of 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-bicyclo[3.2.1] oct-3-yl)-phenyl ester hydrochloride

Add H₂0 (9 mg, 0.5mmol) and TMSC1 (39mg, 0.357mmol) to a solution of 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct-3-yl)-phenyl ester (102mg, 0.297mmol) in 2-butanone (50mL). Then stir the reaction mixture at ambient temperature for 4 hours. Evaporate the mixture under vacuum to give 2,2-dimethyl-propionic acid

3-(2-dimethylaminomethyl -bicyclo[3.2.1]oct-3-yl)-phenyl ester hydrochloride as white solid (112mg, Yield: 100%).1H NMR (400 MHz, Methanol-d4) δ 7.38-7.42 (t, J= 15.6, 1H), 7.20-7.22 (d, J= 7.6, 1H), 7.05 (s, 1H), 6.94-6.96 (m, 1H), 3.08-3.14 (m, 1H), 2.79 (s, 3H), 2.66 (s, 3H), 2.53-2.57 (m, 2H), 2.36 (s, 2H), 2.23 (m, 1H), 1.61-1.85 (m, 8H), 1.39 (s, 9H). The following compounds may be prepared essentially by the method of Example 135.

For compounds of the formula Id, below, Schemes H-J and Preparations and/or Examples 147-164 illustrate methods of preparing them.

Preparation 141

Synthesis of bicyclo[4.1.0]hepti

Add trimethylsulfoxonium iodide (126.3 g, 0.572 mol) to a suspension of sodium hydride (22.9 g, 60% in oil dispersion, 0.572 mol) in dry DMSO (550 mL) at ambient temperature within 10 minutes. Stir the mixture for 1 hour, and then add dropwise a solution of

cyclohex-2-enone (51.2 g, 0.52 mol) in dry DMSO (100 mL) to the reaction mixture. Stir the reaction mixture at 50 °C for additional 2 hours. Pour the reaction mixture into ice-water, and extract the aqueous mixture with CH₂CI₂ (300 mL x 3). The combined organic layers were washed with brine, dried over MgS0₄, concentrated in vacuo. Purify the residue by distillation (55-60 °C, 5 mmHg) to afford bicyclo[4.1.0] heptan-2-one as colorless oil (38.45 g, 66.6 %), MS (m/z): 109 (M-1).

The following compound may be prepared essentially by the method of Preparation 141.

Preparation 143

Synthesis of (bicyclo[4.1.0]hept-2-en-2-yloxy)-trimethyl-silane S

Add dropwise bicyclo[4.1.0]heptan-2-one (43.3 g, 0.393 mol) in dry THF (50 mL) to a solution of LDA (237 mL, 0.472 mol) in THF (500 mL). Stir the reaction mixture for 30 min and then add dropwise TMSCl (64.2 g, 0.59 mol) to the reaction mixture. Stir the resultant solution for additional 1 hour. Pour the mixture into ice water (92 mL) and extract the aqueous mixture with EtOAc (100 mL x 3). The combined organic layers are washed with brine, dried over MgS0₄, filtered and concentrated in vacuo to afford crude (bicyclo[4.1.

0]hept-2-en-2-yloxy)-trimethyl-silane (68.0 g, 95.0 %) as yellowish oil, MS (m/z): 181 (M-1).

The following compound may be prepared essentially by the method of Preparation

Preparation 145

Synthesis of 3-dimethylaminomethyl-bicyclo [4.1.0]hepti

Add (bicyclo[4.1.0]hept-2-en-2-yloxy)-trimethyl-silane (72.9 g, 0.40 mol) to a cooled suspension of Ν,Ν-dimethylmethyleneiminium chloride (48.6 g, 0.52 mol) in CH₂C1₂ (400 mL) at 0 °C. After being stirred for overnight at ambient temperature, dilute the reaction mixture with 2 N HCl (200 mL). After removal of organic layers, wash the aqueous layer with EtOAc (50 mL x 3) and then basify with NaOH to PH = 10. Extract the resultant mixture with EtOAc (100 mL x 4). The combined organic layers are washed with brine, dried over Na₂S0₄, filtered and concentrated in vacuo. Purify the residue by distillation (80 ~ 85 °C, 5 mmHg) to afford

3-dimethylaminomethyl-bicyclo [4.1.0]heptan-2-one (16.0 g, 24.0 %) as colorless oil, MS (m/z): 168 (M+l).

The following compound may be prepared essentially by the method of Preparation 145. Prep

Chemical name Structure Physical data

No.

146 3 -Dimethy laminomethyl- 5 , 5 -dimethy 1-bicy clo [4.1.

0]heptan-2-one <£nr MS (m/z): 196 (M+l).

Example 147

Synthesis of 3-Dimethylaminomethyl-2-(3-hydroxy-phenyl)-bicyclo[4.1.0]hept;

Add a solution of t-BuLi (5.8 mL, 8.68 mmol) via syringe to a solution of

3-bromo-phenol (752 mg, 4.34 mmol) in THF (60 mL) at -78°C under N₂. After being stirred at -78 °C for 1 hour, add a solution of 3-dimethylaminomethyl-bicyclo[4.1.0] heptan-2-one (300 mg, 2.17mmol) in THF (2 mL) to the reaction mixture and stir the reaction mixture at -78 °C for additional 2 hours. Quench the reaction mixture with saturated NH₄CI solution (30 mL). Extract the aqueous resultant mixture with EtOAc (60 mL x 3). The combined organic layers are washed with brine (30 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum. Purify the residue by Preparative HPLC to give

3-dimethylaminomethyl-2-(3-hydroxy-phenyl)-bicyclo[4.1.0]heptan-2-ol as white solid (73 mg, yield: 12.9%). MS (m/z): 262 (M+l).

The following compounds may be prepared essentially by the method of Example 147.

Ex.

Chemical name Structure Physical data

No.

MS (m/z): 290

(M+l), 1H NMR

(Methanol-d4, 400

MHz) 5 7.29 (t, J =

8.0, 1H), 7.03 (m,

3 -Dimethy laminomethy 1- 2H), 6.64 (m, 1H),

2-(3-hydroxy-phenyl)-5,5 2.35 (m, 1H), 1.96 (s,

152 -dimethyl-bicyclo[4.1.0]h 7H), 1.83 (m, 1H),

eptan-2-ol A 1.38 (m, 1H), 1.28 (s,

3H), 1.22 (m, 2H),

1.10 (s, 3H), 1.02 (m,

1H), 0.61 (m, 1H),

0.50 (m, 1H).

Example 153

Synthesis of 3 -dimethy laminomethy 1-2 -(3 -hydroxy-phenyl)-bicyclo [4.1.0]hepti

hydrochloride

Add H₂0 (10 mg, 0.560 mmol) and TMSC1 (33 mg, 0.308 mmol) to a solution of 3-dimethylaminomethyl-2-(3-hydroxy-phenyl)-bicyclo[4.1.0]heptan-2-ol (73 mg, 0.280 mmol) in 2-butanone (10 mL). Then stir the mixture at room temperature for 2 hours. Evaporate the mixture under vacuum to give 3-dimethylaminomethyl-2-(3-hydroxyl -phenyl)-bicyclo[4.1.0]heptan-2-ol hydrochloride as white solid (83 mg, Yield: 100%). 1H NMR (400 MHz, Methanol-d4) δ 7.21-7.25 (t, J=16.0, IH), 7.17-7.18 (t, J= 4.4, IH), 7.11-7.13 (m, IH), 6.76-6.79 (d, J= 10.0, IH), 3.23-3.25 (m, IH), 2.68-2.69 (m, 7H), 2.14-2.17 (m, IH), 2.04-2.09 (m, IH), 1.76-1.81 (m, IH), 1.62-1.64 (m, IH), 1.47-1.49 (m, IH), 1.11-1.16 (m, IH), 0.93-1.05 (m, IH), 0.73-0.84 (m, IH), 0.50-0.53 (m, IH).

The following compounds may prepared essentially by the method of Example 153.

Scheme I

Example 157

Synthesis of 3-dimethylaminomethyl-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo[4.1.0] heptan-2-

Add a solution of t-BuLi (19.4 mL, 25.2 mmol) via syringe to a solution of (3-bromo-5-fluoro-phenoxy)-tert-butyl-dimethyl-silane (6.99 g, 22.9 mmol) in THF (100 mL) at -78 °C under N₂. After being stirred at -78 °C for 1 hour, add dropwise a solution of

3-dimethylaminomethyl-bicyclo[4.1.0]heptan-2-one (2.55 g, 15.3 mmol) to the reaction mixture and stir the reaction mixture at -78 °C for additional 2 hours. Quench the reaction with saturated NH₄CI solution (30 mL). Extract the resultant aqueous mixture with EtOAc (100 mL x 3). The combined organic layers are washed with brine (30 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum. Treat the residue with TBAF (6.00 g, 22.9 mmol) in CH₂C1₂ (80mL) at ambient temperature for 4 hours. Concentrate the mixture, and purify the residue by preparative HPLC to give 3-dimethylaminomethy l-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo[4.1.0] heptan-2-ol as white solid (592 mg, yield: 13.9%). MS (m/z): 280 (M+1). The following compounds may be prepared essentially by the method of Example 157.

Ex.

Chemical name Structure Physical data

No.

158 3 -Dimethy laminomethy 1- 2-(2-fluoro-5-hydroxy-ph J] ^0H

enyl)-bicyclo[4.1.0]hepta

n-2-ol ^H0 < nr MS (m/z): 280 (M+1).

159 3 -Dimethy laminomethy 1- 2-(3 -hydroxy-5 -methyl-p

MS (m/z): 276 (M+1).

henyl)-bicyclo[4.1.0]hept

an-2-ol Example 160

Synthesis of 3-dimethylaminomethyl-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo[4.1.0] hepti

hydrochloride

Add H₂0 (18 mg, 1.0 mmol) and TMSC1 (92 mg, 0.857 mmol) to a solution of 3-dimethylaminomethyl-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo[4.1.0] heptan-2-ol (218 mg, 0.781 mmol) in 2-butanone (70 mL). Then stir the reaction mixture at room temperature for 2 hours. After removal the solvent by evaporation, wash the residue with EtOAc (3 mL x 2) to give 3 -dimethylaminomethyl-2-(3-fluoro-5 -hydroxy-phenyl)- bicyclo[4.1.0]heptan-2-ol hydrochloride as white solid (72 mg, Yield: 67.8%). 1H NMR (400 MHz, D₂0) δ 6.93 (s, 1H), 6.87-6.89 (d, J = 9.6, 1H), 6.42-6.58 (m, 1H), 3.32-3.33 (t, J= 3.2, 1H), 2.98-3.04 (m, 1H), 2.77 (m, 6H), 2.22-2.23 (m, 1H), 2.06 (m, 1H), 1.81-1.85 (m, 2H), 1.61-1.71 (m, 1H), 1.17-1.21 (m, 1H), 1.08-1.10 (m, 1H), 0.83-0.86 (m, 1H), 0.56-0.60 (m, 1H).

The following compounds may be prepared essentially by the method of Example 160.

Scheme J

Example 163

Synthesis of 2,2-dimethyl-propionic acid 3-(3-dimethylaminomethyl-2-hydroxy-bicyclo

[4.1.0]hept-2-yl)-5-fluoro-phenyl ester

Stir a mixture of 3-dimethylaminomethyl-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo [4. 1.0]heptan-2-ol (295 mg, 1.06 mmol), 2,2-dimethyl-propionyl chloride (153 mg, 1.27 mmol) and triethyl-amine (321 mg, 3.18 mmol) in CH₂CI₂ (40 mL) at ambient temperature for 5 hours. Quench the mixture with 10 mL of H₂0. Separate the aqueous layer off, and concentrate the organic layer under reduced pressure. Purify the residue by preparative TLC to give

2,2-dimethyl-propionic acid 3-(3-dimethylaminomethyl-2- hydroxy-bicyclo

[4.1.0]hept-2-yl)-5-fiuoro-phenyl ester as white solid (228 mg, Yield: 59.2%). MS (m/z): 364 (M+l). 1H NMR (400 MHz, Methanol-d4) δ 7.25-7.28 (d, Ji = 10.4, J₂ = 1.6, 1H), 7.14 (s, 1H), 6.76-6.78 (d, Ji = 9.2, J₂ = 2.4, 1H), 2.37-2.46 (m, 1H), 2.15-2.19 (m, 7H), 1.99-2.03 (d, J= 13.2, 1H), 1.82 (m, 2H), 1.53-1.68 (m, 2H), 1.37 (s, 9H), 1.17 (m, 1H), 1.01-1.06 (m, 1H), 0.75-0.81 (m, 1H), 0.48-0.50 (m, 1H).

The following compound may be prepared essentially by the method of Example 163. Ex.

Chemical name Structure Physical data

No.

MS (m/z): 364 (M+l)

1H NMR (400 MHz,

2,2-Dimethyl-prop

Methanol-d4) δ 7.50-7.53 (m, ionic acid 3-(3-di

1H), 7.06-7.15 (m, 1H),

164 methylaminometh

6.96-7.00 (m, 1H), 2.41-2.44 yl-2-hydroxy-bicy

(m, 1H), 2.17-2.22 (m, 2H), clo[4.1.0]hept-2-yl

2.02 (s, 5H), 1.98-2.02 (m, 2H),

)-4-fluoro-phenyl

1.80-1.85 (m, 1H), 1.52-1.64 ester

(m, 2H), 1.38 (s, 9H), 1.13-1.22 (m, 1H), 1.02-1.06 (m, 1H), 0.70-0.72 (m, 1H), 0.59-0.636 (m, 1H).

For compounds of the formula Ie, below, Scheme K and Preparations and/or Examples 165-176 illustrate methods of preparing them.

Preparation 165

(1 R,2R,5S)-2,6,6-trimethylbicyclo[3.1.l]heptan-3-one

Jones reagent: add a mixture of 9 ml of H₂SO₄ and 40 ml of H₂0 to a solution of Cr₂0₃ (15.0 g, 0.15 mol) in H₂0 (20 mL) at 0 °C.

Add dropwise the above Jones reagent to a solution of (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.1]heptan-3-ol (23.1 g, 0.15 mol) in acetone (100 mL) over a period for 2 hours at 0 °C. Stir the resultant mixture for additional 1 hour. Dilute the mixture with 100 mL of water and then extract the aqueous mixture with ether (50 mL X3). The combined organic layers are washed with brine (20 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum to give crude (l R,2R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-one as pale yellow oil (21.3 g, yield: 93.4%), MS (m/z): 151 (M-1).

The following compound may be prepared essentially by the method of Preparation

Preparation 167

(l R,2R,4S,5S)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bicyclo[3.1.1]heptan-3-one

Stir a mixture of (l R,2R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-one (7.6 g, 50.0 mmol), (HCHO)„ (1.8 g, 60.0 mmol), N-methyl-2-phenylethanamine (6.75 g, 50.0 mmol) and 5.0 mL of cone. HCl in MeCN (50 mL) at 70 °C for 3 hours. After removal of the solvent under vacuum, dissolve the residue in H₂0 (30 mL) and washed with EtOAc (20 mL X 2). Basify the aqueous solution with K₂C0₃ to pH = 9 and extract the resultant mixture with EtOAc (30 mL><3). The combined organic layers were washed with brine (20 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum to give crude product as brown oil , which was further purified by silica gel chromatography to give (l R,2R,4S,5S)-2,6,6-trimethyl-4-((methyl(phenethyl)amino) methyl)bicycle[3.1.1]heptan-3-one as pale yellow oil (9.24 g, yield: 61.8%), MS (m/z): 300 (M+1). The following compound may be prepared essentially by the method of Preparation 167.

Example 169

(lR,2R,3S,4S,5S)-3-(3-hydroxyphenyl)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bic yclo [3.1.1 ]heptan-3 -ol

Add a solution of t-BuLi (20 mL, 26.0 mmol) via syringe to a solution of

3-bromo-phenol (2.06 g, 12 mmol) in THF (20 mL) at -78°C under N₂. After being stirred at -78 °C for 1 hour, add a solution of (l R,2R,4S,5S)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl) bicyclo[3.1.1]heptan-3-one (2.99 g, 10 mmol) in THF (2 mL) to the reaction mixture and stir the reaction mixture at -78 °C for additional 2 hours. Quench the reaction with saturated NH₄CI solution (30 mL). Extract the aqueous mixture with EtOAc (60 mL x 3). The combined organic layers are washed with brine (30 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum. Purify the residue by Preparative HPLC to give

(lR,2R,3S,4S,5S)-3-(3-hydroxyphenyl)-2,6,6- trimethyl-4-((methyl(phenethyl)amino)methyl)bicyclo[3.1.1 ]heptan-3-ol as pale yellow oil (0.27 g, yield: 6.9%), MS (m/z): 394 (M+1).

The following compound may be prepared essentially by the method of Example 169.

Ex.

Chemical name Structure Physical data

No.

170 (lR,2Pv,3S,4S,5S)-3-(3-m

ethoxyphenyl)-2,6,6-trim

ethyl-4-((methyl(pheneth MS (m/z): 408 (M+1).

yl)amino)methyl)bicyclo [

3.1.1]heptan-3-ol

171 (lS,2S,3R,4R,5Pv)-3-(3-h OH

ydroxyphenyl)-2,6,6-trim

ethyl-4-((methyl(pheneth MS (m/z): 394 (M+1).

yl)amino)methyl)bicyclo [

3.1.1]heptan-3-ol Ex.

Chemical name Structure Physical data

No.

172 (lS,2S,3R,4R,5R)-3-(3- \

0

methoxyphenyl)-2,6,6-tri

methyl-4-((methyl(phene

MS (m/z): 408 (M+l).

thyl)amino)methyl)bicycl

o[3.1.1]heptan-3-ol

Example 173

(lR,2R,3S,4S,5S)-3-(3-hydroxyphenyl)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bic yclo[3.1.1 ]heptan-3-ol hydrochloride

Add H₂0 (4 mg, 0.25 mmol) and TMSC1 (27 mg, 0.25 mmol) to a solution of (lR,2R,3S,4S,5S)-3-(3-hydroxyphenyl)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bic yclo[3.1.1]heptan-3-ol (100 mg, 0.25 mmol) in 2-butanone (5 mL). Stir the reaction mixture at room temperature for 3 hours. After removal solvent by evaporation, wash the residue with EtOAc (1 mL X 2) and dry under vacuum to give (lR,2R,3S,4S,5S)-3-(3-hydroxyphenyl)-2,6,6-trimethyl -4-((methyl(phenethyl)amino)methyl)bicyclo[3.1.1]heptan-3-ol hydrochloride (93 mg, Yield:

85.3%) as white solid. 1H NMR (400 MHz, D₂O) δ 7.21 -7.32 (m, 7H), 7.97-7.99 (d, J= 7.2, 1H), 6.71-6.78 (dd, J_; = 8.0, J₂ = 22.0, 1H), 2.86-3.33 (m, 5H), 2.43-2.68 (m, 7H), 2.11-2.20 (m, 2H), 1.73-1.75 (m, 1H), 1.23-1.25 (d, J= 5.6, 3H), 1.04-1.05 (d, J= 4.4, 3H), 0.69-0.71 (d, J= 5.6, 3H). [a]¾ = -8.6 (c= 1.4 mg/niL, MeOH).

The following compounds may be prepared essentially by the method of Example 173.

Ex.

Chemical name Structure Physical data

No.

174 (lR,2R,3S,4S,5S)-3-(3-m Ή NMR (400 ethoxyphenyl)-2,6,6-trim MHz, D₂O) δ 7.02-7.26 (m, ethyl-4-((methyl(pheneth

7H), 6.74-6.86 (m, 2H), yl)amino)methyl)bicyclo [

3.64-3.66 (d, J= 10.4, 3H),

3.1.1]heptan-3-ol

2.76-3.22 (m, 5H), 2.32-2.53 hydrochloride

(m, 7H), 2.02-2.14 (m, 2H), 1.64-1.67 (m, 1H), 1.14-1.56 (d, J= 6.8, 3H), 0.95-0.97 (d,

J= 6.4, 3H), 0.63 (s, 3H).

[a]¾ = -16.1 (c= 6.4 mg/mL,

MeOH)

175 (lS,2S,3R,4R,5R)-3-(3-h

ydroxyphenyl)-2,6,6-trim MS (m/z): 394 (M+l).

ethyl-4-((methyl(pheneth

yl)amino)methyl)bicyclo [ [a]¾ = 9.3 (c = 4.5 mg/mL,

3.1.1]heptan-3-ol MeOH)

hydrochloride Ex.

Chemical name Structure Physical data

No.

176 (lS,2S,3R,4R,5R)-3-(3- methoxyphenyl)-2,6,6-tri MS (m/z): 408 (M+l).

methyl-4-((methyl(phene

[α]¾ = 14.3 (c = 6.0 mg/mL, thyl)amino)methyl)bicycl

o[3.1.1]heptan-3-ol MeOH)

hydrochloride

For compounds of the formula If, below, Scheme L and Preparations and/or Examples 177-180 illustrate methods of preparing them.

Scheme L

Preparation 177

Synthesis of (2,3 ,3a,6,7,7a-hexahydro- 1 H-inden-4-yloxy)trimethylsilane S

Add dropwise hexahydro-lH-inden-4(2H)-one (1.6 g, 11.6 mmol) in dry THF (5 mL) to a solution of LDA (23.2 mL, 23.2 mmol) in THF (30 mL). Stir the reaction mixture for 30 min and then add dropwise TMSCl (3.5 g, 32.0 mmol) to the reaction mixture. Stir the resultant solution for additional 1 hour. Pour the mixture into ice water (50 mL) and extract the aqueous mixture with EtOAc (50 mL x 3). The combined organic layers are washed with brine, dried over MgS0₄, filtered and concentrated in vacuo to afford crude

(2,3,3a,6,7,7a-hexahydro-lH-inden-4-yloxy) trimethylsilane (2.45 g, 100 %) as yellowish oil, MS (m/z): 209 (M-l).

Preparation 178

5-((dimethylamino)methyl)hexahydro-lH-inden-4(2H)-one

Add (2,3,3a,6,7,7a-hexahydro-lH-inden-4-yloxy) trimethylsilane (2.45 g, 1 1 .6 mmol) to a cooled suspension of Ν,Ν-dimethylmethyleneiminium iodide (2.78 g, 15.0 mmol) in CH₂CI₂ (60 mL) at 0 °C. After being stirred for overnight at ambient temperature, dilute the reaction mixture with 2 N HC1 (20 mL). After removal of organic layers, wash the aqueous layer with EtOAc (30 mL x 3) and then basify with NaOH to PH = 10. Extract the resultant mixture with EtOAc (50 mL x 4). The combined organic layers are washed with brine, dried over Na₂S0₄, filtered and concentrated in vacuo to afford 5-((dimethylamino)methyl)hexahydro-lH-inden- 4(2H)-one (623 mg, 27.5 %) as oil, MS (m/z): 196 (M+l).

Example 179

5 -((dimethylamino)methyl)-4-(3 -hydroxyphenyl)octahydro- 1 H-inden-4-ol

Add a solution of t-BuLi (2.1 mL, 3.07 mmol) via syringe to a solution of 3-bromo-phenol (569 mg, 3.076 mmol) in THF (50 mL) at -78°C under N₂. After being stirred at -78 °C for 1 hour, add a solution of 35 -((dimethyl amino)methyl) hexahydro-lH-inden-4(2H)-one (300 mg, 1.54 mmol) in THF (2 mL) to the reaction mixture and stir the reaction mixture at -78 °C for additional 2 hours. Quench the reaction mixture with saturated NH₄C1 solution (30 mL). Extract the aqueous resultant mixture with EtOAc (50 mL x 3). The combined organic layers are washed with brine (30 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum. Purify the residue by Preparative HPLC to give 5-((dimethylamino)methyl)-4-(3-hydroxyphenyl) octahydro-lH-inden-4-ol (92 mg, yield: 19.7%). MS (m/z): 290 (M+l). Example 180

5 -((dimethylamino)methyl)-4-(3 -hydroxyphenyl)octahydro- 1 H-inden-4-ol hydrochloride

Add H₂0 (10 mg, 0.54 mmol) and TMSC1 (35 mg, 0.33 mmol) to a solution of

5-((dimethylamino)methyl)-4-(3-hydroxyphenyl)octahydro-lH-inden-4-ol (78 mg, 0.27 mmol) in 2-butanone (10 mL). Then stir the mixture at room temperature for 12 hours. Evaporate the mixture under vacuum to give 5-((dimethylamino)methyl)-

4-(3-hydroxyphenyl)octahydro-lH-inden-4-ol hydrochloride as a mixture of 4 diastereoisomers (91 mg, Yield: 100%).

Example 181

(+)-(lS,2R,3R,5R)-2-((dimethylamino)methyl)-3-(3-hydroxyphenyl)bicyclo[3.2.1]octan-3-ol and (-)-(lR,2S,3S,5S)-2-((dimethylamino)methyl)-3-(3-hydroxyphenyl)bicyclo[3.2.1]octan-3-ol.

Separate 0.5 g of 2-((dimethylamino)methyl)-3-(3-hydroxyphenyl)bicyclo[3.2.1] octan-3-ol (1.82 mmol) by SFC to afford (+)-(lS,2R,3R,5R)-2-((dimethylamino) methyl)-3- (3-hydroxyphenyl)bicyclo[3.2.1]octan-3-ol (8 mg, Yield: 3.2%; MS (m/z): 276 (M+1)) and (-)-(lR,2S,3S,5S)-2-((dimethylamino)methyl)-3-(3-hydroxyphenyl) bicyclo[3.2.1]octan-3-ol (135 mg, Yield: 54.0%>; MS (m z): 276 (M+1)) as white solids. The relative configuration of two enantioisomers is confirmed by 2D NMR and the absolute configuration of the two

enantioisomers is determined by x-ray analysis. (+)-Enantioisomers show better biological activity than (-)-enantioisomer in bioassay(s).

Example 182

(S)-3-((lS,2R,3R,5R)-2-((dimethylamino)methyl)-3-hydroxybicyclo[3.2.1]octan-3-yl)phenyl

2-phenylpropanoate hydrochloride

Stir a solution of (S)-2-phenylpropanoic acid (300 mg, 2.0 mmol) in 5 mL of oxalyl chloride for 3 hours at room temperature. After removal of solvent under vacuum,

(S)-2-phenylpropanoyl chloride is obtained as pole yellow oil. Dissolve the oil in 10 mL of CH₂C1₂. Add (lS,2R,3R,5R)-2-((dimethylamino)methyl)-3-(3-hydroxyphenyl) bicyclo[3.2.1] octan-3-ol (400 mg, 1.45 mmol) and Et₃N (293 mg, 2.9 mmol) to the solution. Stir the resultant mixture at room temperature for additional 3 hours. After addition of 20 mL of water, basify the mixture with K₂C0₃ to pH = 10, and extract the aqueous mixture with EtOAc (20 mL X 3). The combined organic layers are washed with brine (20 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (CfLCbiMeOH = 30: 1) to afford (S)-3-((lS,2R,3R,5R)-2-((dimethylamino)methyl)-3-hydroxybicyclo[3.2.1]octan -3-yl) phenyl 2-phenylpropanoate (500 mg, 84.7%; MS (m/z): 408 (M+l)) as yellow oil. Stir (S)-3-((lS,2R,3R,5R)-2-((dimethylamino)methyl)-3-hydroxybicyclo[3.2.1]octan-3-yl)phenyl 2-phenylpropanoate (250 mg, 0.61 mmol) with ¾0 (11 mg, 0.61 mmol) and TMSC1 (66 mg, 0.61 mmol) in 2-butanone (5 mL) for 3 hours. Collect the precipitate by filtration to afford (S)-3-((lS,2R,3R,5R)-2 (dimethylamino)methyl)-3- hydroxybicyclo[3.2.1]octan-3-yl)phenyl 2-phenylpropanoate hydrochlorid (215 mg, Yield: 79.3%) as white solid. The absolute configuration of its hydrochloride salt form was confirmed by x-ray analysis.

1H NMR (400 MHz, DMSO) δ 9.81 (br, 1H), 7.31-7.41 (m, 7H), 7.14 (s, 1H), 6.87-6.90 (m, 1H), 5.01 (s, 1H), 4.08-4.10 (m, 1H), 3.02-3.08 (m, 1H), 2.42-2.58 (m, 4H), 2.12-2.26 (m, 6H), 1.90-1.99 (m, 2H), 1.75-1.80 (m, 2H), 1.51-1.59 (m, 6H).

The following compound may be prepared essentially by the method of Example 182.

Example 184

3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-phenol and 3-((l S,5R)-2-((dimethylamino)methyl)bicyclo[3.2.1 ]oct-2-en-3-yl)phenol

Add TsOH (5.0 g, 29.1 mmol) to a solution of 2-dimethylaminomethyl- 3-(3-hydroxy-phenyl)-bicyclo[3.2.1]octan-3-ol (4.8 g, 17.5 mmol) in toluene (150 mL). Heat the reaction mixture to reflux for 2 hours and then quench the reaction by addition of saturated aqueous K₂CO₃ (20 mL). Extract the aqueous layer with EtOAc (60 mL x 3). The combined organic layers are washed with brine, dried over Na₂S0₄ and evaporated under vacuum. Purify the residue by preparative HPLC to yield 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)- phenol (2.27 g, 50.2 %; MS (m/z): 258 (M+l)) and

3-(2-((dimethylamino)methyl)bicyclo[3.2.1]oct-2-en-3-yl) phenol (517 mg, 11.5 %; MS (m/z): 258 (M+l)) as white solid. Two isomers show comparable biological activity in bioassay.

For compounds of the formula Ig, below, Scheme M and Preparations and/or Examples 185-187 illustrate methods of preparing them.

Ig

Scheme M

Preparation 185

5 -dimethylaminomethyl-spiro [2.5 ]octan-6-one

Stir a mixture of spiro[2.5]octan-6-one (252 mg, 2.03 mmol), (HCHO)_n (61 mg, 2.03 mmol), dimethylamine hydrochloride (166 mg, 2.03 mmol) and 0.3 mL of cone. HC1 in MeCN (30 mL) at 60 °C for 6 hours. Quench the reaction with saturated aqueous NH₄C1 solution (15 mL). Basify the aqueous solution with K₂CO₃ to pH = 9. Extract the aqueous mixture with EtOAc (30 mL x 2). The combined organic layers are washed with brine (15 mL), dried over Na₂S0₄, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (CH₂Cl₂:MeOH = 30: 1) to afford 5-Dimethylaminomethyl-spiro[2.5]octan-6-one as brown oil (142mg, yield: 38.4%). MS (m/z): 182 (M+l).

Example 186

5 -dimethylaminomethyl-6-(2-fluoro-5 -hydroxy-phenyl)-spiro [2.5 Joctan -6-0I

Cool a solution of (3-bromo-4-fluoro- phenoxy)-tert-butyl-dimethyl-silane (472 mg, 1.547 mmol) in THF (40 mL) to -78 °C under N₂. Then add dropwise a solution of n-BuLi (0.63 mL, 1.547 mmol) in hexane via syringe to the reaction solution. After being stirred at -78 °C for 2 hour, add dropwise a solution of 5-Dimethylaminomethyl-spiro[2.5]octan-6-one (70 mg, 0.387 mmol) in THF (1 mL) to the reaction mixture and stir the mixture at -78 °C for additional 2 hours. Quench the reaction with 20 mL of diluted HCl (2N), and stir at ambient temperature for 2 hours. Basify the resultant mixture with K₂CO₃ to pH = 9, and extract with EtOAc (30 mL X 2). The combined organic layers are washed with brine, dried over Na₂S0₄, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (CH₂C1₂ to CH₂Cl₂:MeOH = 10: 1) to afford 5-dimethylaminomethyl -6-(2-fluoro-5-hydroxy-phenyl)-spiro[2.5]octan-6-ol as white solid (41mg, yield: 36.3%). MS (m/z): 294 (M+l).

Example 187

5 -dimethylaminomethyl-6-(2-fluoro-5 -hydroxy-phenyl)-spiro [2.5 Joctan -6-0I hydrochloride

Add H₂0 (9 mg, 0.500 mmol) and TMSC1 (18 mg, 0.167 mmol) to a solution of 5-dimethylaminomethyl-6-(2-fluoro-5-hydroxy-phenyl)-spiro[2.5]octan-6-ol (41 mg, 0.139 mmol) in 2-butanone (30 mL). Stir the mixture at 0 °C for 2 hours. Concentrate the mixture under vacuum to give 5-dimethylaminomethyl-6-(2-fluoro -5-hydroxy-phenyl)-spiro[2.5]octan-6-ol

hydrochloride as white solid (46 mg, Yield: 100%). 1H NMR (400 MHz, D₂0) δ 7.13-7.15 (d, J; = 6.8, J₂ = 3.2, 1H), 6.93-6.98 (d, J; = 12.0, J₂ = 8.8, 1H), 6.69-6.73 (m, 1H), 3.05-3.10 (m, 1H), 2.65-2.76 (m, 8H), 2.44-2.45 (m, 1H), 2.27-2.35 (m, 2H), 1.70-1.74 (m, 1H), 0.96-0.98 (m, 1H), 0.79-0.82 (m, 1H), 0.45 (m, 1H).

Mu opioid agonists, such as morphine, are well known to control pain (Tschenkte et al., Tapentadol Hydrochloride - Analgesic, Mu-opioid receptor agonist, Noradrenaline reuptake inhibitor. E. Drugs Fut 2006, 31(12): 1053). However, mu opioid agonists also can cause several undesired side effects such as nausea, emesis, constipation, mental clouding, and respiratory depression. In addition, use of opioids for an extended period of time (as is needed in chronic pain) can result in physical dependence and addiction.

Tramadol, a mu-opioid agonist, has not been associated with clinically significant side effects such as respiratory depression, constipation, or sedation (Id.). In addition, extended use of Tramadol does not lead to tolerance, dependence, and addiction (Id.). Tramadol is believed to exert its chronic pain relief through a combination of three mechanisms of action; mu opioid agonism and serotonin and norepinephrine reuptake inhibition (Raffa et al., Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 Jan; 260(l):275-85). Because Tramadol relieves pain through a combination of mechanisms of action it is able to relieve pain even though it is a much less potent mu opioid receptor agonist compared to morphine. The reason for the better side effect profile of Tramadol as compared to morphine is believed to be a result of Tramadol's lower affinity for the mu opioid receptor. A molecule that, like Tramadol, controls chronic pain by multiple mechanisms of action is desired, and a compound which possessed a favorable side effect profile, particularly as compared to morphine, and that also was longer acting was sought. Preferably, a molecule that needed to be administered at most 1 time per day for extended pain relief is sought.

Molecules that are mu opioid agonists and also norepinephrine and/or serotonin reuptake inhibitors are preferably selected for evaluation in the rat tail flick model. In order to be selected for the rat tail flick model the compound needs to demonstrate an EC50 of less than 50 micromolar in a functional assay for mu opioid receptor activation. In addition, the active species needs to demonstrate an IC50 of less than 500 micromolar in a functional assay for inhibition of norepinephrine and/or serotonin reuptake. Activity of the corresponding phenols are used to select ether and ester prodrugs for evaluation in the rat tail flick model. The Tail Flick Assay, based upon the methods of D 'Amour & Smith (J. Pharmacol. Exp. Therap., 72: 74-79, 1941), is used to measure loss of pain sensation in the rat tail, allowing the experimenter to screen drugs for analgesic effect. Since then, the method has been used in a number of publications. For example, it was used to evaluate the analgesic effect of O-alkyl derivatives of tramadol by Liming Shao and Michael Hewitt etc. (Boiorganic & Medicinal Chemistry Letters, 18:1674-1680, 2008).

A Tail Flick Unit is used to measure tail flick latency in response to heat. The unit consists of an infrared (I.R.) source (50W bulb) with adjustable intensity that is focused through a flush mounted window on the upper panel of the unit and onto the rat tail. Once I.R. source is focused on the rat tail and turned on, a timer starts. When the thermal threshold for pain is reached and the rat flicks its tail, the I.R source automatically shuts off and the timer stop, displaying the latency time.

On the day of experiment, the animals are tested to determine baseline latency. Each rat is given one test to determine latency to tail flick with a cut off 10 seconds. Baselines are recorded and those animals with a baseline latency of 2-5 seconds are used in the experiment.

Animals are divided into several groups according to the baseline latency. The Tail-flick latencies are measured at different timepoints for up to 180 minutes after administration of vehicle or test articles. If treatment group continues to display pain control after 180 minutes, additional measurements are taken every 60 minutes until pain control is no longer observed.

I.R. Source is set at 40 units (determined to elicit tail flick response in desired 2-5 seconds in na^'ive animals). A cut off time of 10 seconds is set to avoid tissue damage, in the event that the animal does not flick its tail.

Test articles or vehicle are administered by intravenous (IV) injection through the tail vein or by oral gavage at time 0. Animals are gently restrained and held on top of a tail flick unit. The tail is then wiped clean with a cotton square and placed over the I.R. source so that the beam is focused at approximately midway the length of the tail. After the rat is in position, the I.R. source is turned on. When the thermal threshold for pain is reached, the rat flicked its tail and the I.R. source automatically shuts off. Latency time (in seconds) is then recorded.

Data are recorded and graphed as %MPE (Maximum Possible Effect). % MPE is calculated using the following formula: % MPE = [(Test latency - Baseline latency) / (Cut off latency (10 sec.'s) - Baseline latency)] * 100

Compounds were administered by the IV route in 20%

2-hydroxypropyl-beta-cyclodextrin (20%> ΗΡ-β-CD). The dose levels of test article were 2.5, 5, or 20 mg/kg. Examples 2, 3, 13, 40, 77, 78, 114, and Tramadol provided at least 50% MPE at 20 mg/kg. Compounds 5, 8, 17, 105, 107, 148, 158, and 159 provided at least 50% MPE at 5 mg/kg. Compounds 82, 84, and 116 provided at least 50%> MPE at 2.5 mg/kg.

Compounds were administered by oral gavage in 0.5%> methylcellulose at 20 or 30 mg/kg. Examples 2, 3, 13, 115, and Tramadol provided at least 50%> MPE at 30 mg/kg.

Compounds 5, 39, 65, 106, and 115 provided at least 50% MPE at 20 mg/kg.

The data above supports the contention the compounds are useful in controlling pain.

Claims

WE CLAIM:

1. A compound, or salt thereof, of formula I:

wherein A is

R¹ is hydrogen, C₁-C₅ alkyl, C₁-C₅ alkoxy, C₁-C₅ haloalkyl, C₁-C₅ alkanol, -(C₁-C₅ alkyl)phenyl, or phenyl, or a group of the formula -C(0)-R¹², where R¹² may be C₁-C₅ alkyl, C₁-C5 alkoxy, C₁-C5 haloalkyl, C₁-C5 alkanol, -(C₁-C5 alkyl)phenyl, or phenyl;

R² is hydrogen, C₁-C₅ alkyl, C₁-C₅ alkoxy, halogen, C₁-C₅ haloalkyl, or C₁-C₅ haloalkoxy;

R⁴ is hydrogen, C₁-C₅ alkyl, or -(C₁-C₅ alkyl)phenyl;

R⁵ is hydrogen, C₁-C₅ alkyl, or -(C₁-C₅ alkyl)phenyl;

R⁶ is hydrogen, hydroxy, or is absent;

R⁷ is hydrogen;

R⁸ is hydrogen or methyl;

R⁹ is hydrogen or methyl;

R¹⁰ is hydrogen;

R¹¹ is hydrogen or C₁-C5 alkyl;

or R⁷ and R¹⁰ combine to form -CH₂- or -(CH₂)₂-; or R⁸ and R⁹ combine to form a cyclopropyl group with the carbon to which they are attached:

or R¹⁰ and R¹¹ combine to form -CH₂- or -(CH₂)₃-

2. The compound of claim 1 wherein A is selected from

3. The compound of claim 2 of the formula la:

la.

4. The compound of claim 3 wherein it is

2-dimethylaminomethyl-3-(3-methoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(3-fluoro-5-methoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(5-methoxy-2-trifluoromethoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol; 2-dimethylaminomethyl-3-(2-fluoro-5-methoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(4-fluoro-3-methoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol; 2-dimethylaminomethyl-3-(2-fluoro-3-methoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2- dimethylaminomethyl-3-(3-methoxy-5-methyl-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

3- (2-chloro-5-methoxy-phenyl)-2-dimethylaminomethyl-bicyclo[3.2.1 ]octan-3-ol;

3-(3-chloro-5-methoxy-phenyl)-2-dimethylaminomethyl-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(5-methoxy-2-methyl-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(3-methoxy-4-methyl-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(3-hydroxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(2-fluoro-5-hydroxy-phenyl)-bicyclo[3.2.1 Joctan -3-ol;

2-dimethylaminomethyl-3-(3-fluoro-5-hydroxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(3-hydroxy-5-trifluoromethyl-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(5-hydroxy-2-trifluoromethoxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol; 2-dimethylaminomethyl-3-(3-hydroxy-4-trifluoromethyl-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(4-fluoro-3-hydroxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(2-fluoro-3-hydroxy-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2- dimethylaminomethyl-3-(3-hydroxy-5-methyl-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

3- (2-chloro-5-hydroxy-phenyl)-2-dimethylaminomethyl-bicyclo[3.2.1 ]octan-3-ol;

3-(3-chloro-5-hydroxy-phenyl)-2-dimethylaminomethyl-bicyclo[3.2.1 ]octan-3-ol;

2-dimethylaminomethyl-3-(5-hydroxy-2-methyl-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

2- dimethylaminomethyl-3-(3-hydroxy-4-methyl-phenyl)-bicyclo[3.2.1 ]octan-3-ol;

3 - (3 ,4-difluoro-5 -hydroxy-phenyl)-2-dimethylaminomethyl-bicyclo [3.2.1 ]octan-3 -ol;

2-dimethylaminomethyl-3-(2-fluoro-5-hydroxy-phenyl)-bicyclo[3.2.1 Joctan -3-ol;

2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicycle[3.2.1]

oct-3-yl)-4-fluoro-phenyl ester;

benzoic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicyclo[3.2.1]oct-3-yl)-4-fluoro-phenyl ester; 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicyclo[3.2. l]oct-3-yl) -phenyl ester;

benzoic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicyclo[3.2.1]oct-3-yl)-phenyl ester;

2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicyclo[3.2. l]oct-3-yl) -5-fluoro-phenyl ester; or

benzoic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicyclo[3.2.1]oct-3-yl)-5-fluoro-phenyl ester; or a salt thereof.

6. The compound of claim 5 wherein it is

3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-phenol;

[3-(3-methoxy-phenyl)-bicyclo[3.2.1 ]oct-3-en-2-ylmethyl]-dimethyl-amine;

[3-(5-methoxy-2-trifluoromethoxy-phenyl)-bicyclo[3.2.1 ]oct-3-en-2-ylmethyl]-dimethyl-amine; 3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-4-trifluoromethoxy-phenol;

[3-(3-fluoro-5-methoxy-phenyl)-bicyclo[3.2.1 ]oct-3-en-2-ylmethyl]-dimethyl-amine;

3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-5-fluoro-phenol;

[3-(2-fluoro-5-methoxy-phenyl)-bicyclo[3.2.1 ]oct-3-en-2-ylmethyl]-dimethyl-amine;

3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-4-fluoro-phenol;

[3-(3-methoxy-5-methyl-phenyl)-bicyclo[3.2.1 ]oct-3-en-2-ylmethyl]-dimethyl-amine;

3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-5 -methyl-phenol;

3-chloro-5-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-phenol;

[3-(5-methoxy-2-methyl-phenyl)-bicyclo[3.2.1 ]oct-3-en-2-ylmethyl]-dimethyl-amine;

3- (4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-4-methyl-phenol;

4- chloro-3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-phenol;

2,2-dimethyl-propionic acid 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct- 2-en-3-yl)-phenyl ester;

benzoic acid 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenyl ester;

2,2-dimethyl-propionicacid 3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)

-5-fluoro-phenyl ester;

isobutyric acid 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-5-fluoro-phenyl ester; 2,2-dimethyl-propionic acid 3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl) -4-fluoro-phenyl ester; or

isobutyric acid 3-(4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-4-fluoro-phenyl a salt thereof.

7. The compound of claim 2 wherein it is of the formula Ic:

8. The compound of claim 7 wherein it is:

3-(2-dimethylaminomethyl-bicyclo[3.2.1 ]oct-3-yl)-phenol;

[3-(3-methoxy-phenyl)-bicyclo[3.2.1 ]oct-2-ylmethyl]-dimethyl-amine;

3-(2-dimethylaminomethyl-bicyclo[3.2.1 ]oct-3-yl)-5-fluoro-phenol;

[3-(3-fluoro-5-methoxy-phenyl)-bicyclo[3.2.1 ]oct-2-ylmethyl]-dimethyl-amine;

3-(2-dimethylaminomethyl-bicyclo[3.2.1 ]oct-3-yl)-4-fluoro-phenol;

[3-(2-fluoro-5-methoxy-phenyl)-bicyclo[3.2.1 ]oct-2-ylmethyl]-dimethyl-amine;

3-(2-dimethylaminomethyl-bicyclo[3.2.1 ]oct-3-yl)-5 -methyl-phenol;

[3-(3-methoxy-5-methyl-phenyl)-bicyclo[3.2.1 ]oct-2-ylmethyl]-dimethyl-amine;

2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct -3-yl)-phenyl ester; benzoic acid 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct-3-yl)-phenyl ester;

2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-bicyclo[3.2. l]oct-3-yl)-5-fluoro-phenyl ester; isobutyric acid 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct-3-yl)-5-fluoro-phenyl ester; 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-bicyclo[3.2. l]oct-3-yl)-4-fluoro-phenyl ester; or isobutyric acid 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct-3-yl)-4-fluoro-phenyl ester; or a salt thereof.

9. The compound of claim 2 wherein it is of the formula Id:

Id.

The compound of claim 9 wherein it

3 -dimethylaminomethyl-2-(3 -hydroxy-phenyl)-bicyclo [4.1.0]heptan-2-ol;

3-dimethylaminomethyl-2-(3-methoxy-phenyl)-bicyclo[4.1.0]heptan-2-ol;

3 -dimethylaminomethyl-2-(3 -fluoro-5 -methoxy-phenyl)-bicyclo [4.1.0]heptan-2-ol;

3 -dimethylaminomethyl-2-(5 -methoxy-2-methyl-phenyl)-bicyclo [4.1.0]heptan-2-ol;

3 -dimethylaminomethyl-2-(3 -methoxy-phenyl)-5 ,5 -dimethyl-bicyclo [4.1.0]heptan-2-ol;

3 -dimethylaminomethyl-2-(3 -hydroxy-phenyl)-5 ,5 -dimethyl-bicyclo [4.1.0]heptan-2-ol;

3 -dimethylaminomethyl-2-(3 -fluoro-5 -hydroxy-phenyl)-bicyclo [4.1.0] heptan-2-ol;

3 -dimethylaminomethyl-2-(2-fluoro-5 -hydroxy-phenyl)-bicyclo [4.1.0]heptan-2-ol;

3 -dimethylaminomethyl-2-(3 -hydroxy-5 -methyl-phenyl)-bicyclo [4.1.0]heptan-2-ol;

2,2-dimethyl-propionic acid 3-(3-dimethylaminomethyl-2-hydroxy-bicyclo[4.1.0]hept-2-yl)-

5-fluoro-phenyl ester; or

2,2-dimethyl-propionic acid 3-(3-dimethylaminomethyl-2-hydroxy-bicyclo[4.1.0]hept-2-yl) -4-fluoro-phenyl ester; or a salt thereof.

11. The compound of claim 2 wherein it is of the formula Ie:

le.

12. The compound of claim 11 wherein it is

(lR,2R,4S,5S)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bicyclo[3.1.1]heptan-3-one; (1 S,2S,4R,5R)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bicyclo[3.1.1 ]heptan-3-one; (lR,2R,3S,4S,5S)-3-(3-hydroxyphenyl)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bic yclo [3.1.1 ]heptan-3 -ol;

(lR,2R,3S,4S,5S)-3-(3-methoxyphenyl)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bic yclo [3.1.1 ]heptan-3 -ol;

(lS,2S,3R,4R,5R)-3-(3-hydroxyphenyl)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bic yclo [3.1.1 ]heptan-3 -ol;

(lS,2S,3R,4R,5R)-3-(3-methoxyphenyl)-2,6,6-trimethyl-4-((methyl(phenethyl)amino)methyl)bic yclo[3.1.1]heptan-3-ol; or a salt thereof.

13. The compound of claim 2 wherein it is of the formula If:

14. The compound of claim 13 wherein it is

5-((dimethylamino)methyl)-4-(3-hydroxyphenyl)octahydro-lH-inden-4-ol, or a salt thereof.

15. The compound of claim 2 wherein it is

(+)-(lS,2R,3R,5R)-2-((dimethylamino)methyl)-3-(3-hydroxyphenyl)bicyclo[3.2.1]octan-3-ol; (-)-(lR,2S,3S,5S)-2-((dimethylamino)methyl)-3-(3-hydroxyphenyl)bicyclo[3.2.1]octan-3-ol; (S)-3-((lS,2R,3R,5R)-2-((dimethylamino)methyl)-3-hydroxybicyclo[3.2.1]octan-3-yl)phenyl 2-phenylpropanoate hydrochloride; (S)-3-((lR,2S,3S,5S)-2 (dimethylamino)methyl)-3-hydroxybicyclo[3.2.1]octan-3-yl)phenyl

2- phenylpropanoate hydrochloride;

3- (4-dimethylaminomethyl-bicyclo[3.2.1 ]oct-2-en-3-yl)-phenol;

3-((lS,5R)-2-((dimethylamino)methyl)bicyclo[3.2.1]oct-2-en-3-yl)phenol; and salts thereof.

A compound of claim 2 wherein it is of the formula I

Ig.

The compound of claim 16 where it

5-dimethylaminomethyl-6-(2-fluoro-5-hydroxy-phenyl)-spiro[2.5]octan -6-ol, or a salt thereof.

18. A pharmaceutical formulation comprising a compound of any of claims 1 through 17 and one or more pharmaceutically acceptable carriers.

19. The pharmaceutical formulation of claim 18 wherein it further comprises at least one additional active ingredient.

20. The pharmaceutical formulation of claim 18 wherein it is a human pharmaceutical formulation.

21. The pharmaceutical formulation of claim 18 wherein it is veterinary pharmaceutical formulation.

22. A method of controlling pain in a mammal in need thereof comprising administering an effective amount of a compound of any of claims 1 through 17 to said mammal.

23. The method of claim 22 wherein at least one other active ingredient is administered to said mammal.

24. The method of claim 22 wherein said mammal is a human.

25. The method of claim 22 wherein said mammal is a companion animal.

26. The method of claim 25 wherein said companion animal is a dog or cat.

27. A compound or salt according any one of claims 1-17 for use in therapy.

28. A compound or salt according to anyone of claims 1-17 for use in controlling pain.